Psoriatic Arthritis (PsA) Archives

Global recruitment associated with higher placebo responses in PsA trials

Presented By

Dr Andreas Kerschbaumer, Medical University of Vienna, Austria

Conference

ACR 2024

Type

Peer-reviewed article

13 January 2025 11:32

Meet the Trialist: Prof. Philip J. Mease on the bimekizumab clinical trial program in psoriatic arthritis

Expert

Prof. Philip J. Mease, Swedish Medical Center/Providence-St. Joseph Health, Seattle, WA, USA

Trial

Phase 3, BE OPTIMAL, BE COMPLETE, BE VITAL

Conference

ACR 2024

23 December 2024 14:39

PsoBest registry: Biologics dominate treatment for moderate-to-severe psoriasis

Presented By

Prof. Matthias Augustin, University Medical Center Hamburg-Eppendorf, Germany

Trial

PsoBest registry

Conference

EADV 2024

Type

Peer-reviewed article

6 November 2024 12:23

Advanced therapies show promising results in PsA real-world study

Presented By

Prof. Dennis McGonagle, University of Leeds, UK

Trial

PRO-SPIRIT

Conference

EULAR 2024

Type

Peer-reviewed article

29 July 2024 14:38

Small protein targeting IL-17A effective in PsA management

Presented By

Prof. Philip Mease, University of Washington; Swedish Medical Center, WA, USA

Trial

Phase 2

Conference

EULAR 2024

Type

Peer-reviewed article

29 July 2024 14:37

How close are we to personalised medicine in psoriatic arthritis?

Presented By

Prof. Ennio Lubrano, University of Molise, Ital

Conference

IFPA 2024

Type

News article

17 July 2024 14:38

Using advances in the genetics of psoriatic disease to better predict treatment response

Presented By

Prof. Carl Goodyear, University of Glasgow, Scotland

Conference

IFPA 2024

Type

News article

17 July 2024 14:28

The unfavourable role of obesity in psoriatic disease

Presented By

Prof. Ulrich Mrowietz, University Medical Center Schleswig-Holstein, Germany

Conference

IFPA 2024

Type

News article

17 July 2024 14:13

Managing obesity and fibromyalgia in psoriatic disease

Presented By

Prof. Philip Mease, University of Washington, USA

Conference

IFPA 2024

Type

News article

17 July 2024 14:08

Improving outcomes in pregnancy and psoriatic disease

Presented By

Dr Oseme Etomi, Guy's and St Thomas' Hospital, UK

Conference

IFPA 2024

Type

News article

17 July 2024 13:44

Towards prevention of psoriatic arthritis in patients with psoriasis

Presented By

Prof. Laura Coates, University of Oxford, UK

Conference

IFPA 2024

Type

News article

17 July 2024 13:39

Itch and pain are major components of psoriatic disease and require management

Presented By

Prof. Adam Reich; Dr Anushka Irani

Conference

IFPA 2024

Type

News article

17 July 2024 12:07

Biologics in psoriatic arthritis: where we are and where we are headed

Presented By

Dr Vinod Chandran

Conference

IFPA 2024

Type

News article

17 July 2024 11:55

Ixekizumab resolves nail psoriasis better than adalimumab in PsA

Presented By

Prof. Dennis McGonagle, University of Leeds, United Kingdom

Trial

Phase 4, SPIRIT-H2H

Conference

ACR 2023

Type

News article

1 December 2023 12:36

IV secukinumab safe and effective for long-term treatment of active PsA

Presented By

Prof. Iain McInnes, University of Glasgow, Scotland

Trial

FUTURE 2-5

Conference

ACR 2023

Type

News article

1 December 2023 12:04

Apremilast in early oligoarticular PsA: phase 4 study results

Presented By

Dr Philip Mease, University of Washington, WS, USA

Trial

Phase 4, FOREMOST

Conference

ACR 2023

Type

News article

1 December 2023 12:03

Dual IL-17 blockade yields efficacy on joints and skin

Presented By

Prof. Diamant Thaçi, University of Lübeck, Germany

Trial

Phase 3, BE OPTIMAL; BE COMPLETE

Conference

EADV 2023

Type

Peer-reviewed article

28 November 2023 12:27

IL-23 blockers may lower the risk of developing inflammatory and psoriatic arthritis

Presented By

Prof. Bruce Strober, Yale University School of Medicine, USA

Conference

EADV 2023

Type

Peer-reviewed article

28 November 2023 12:01

Strategies for Early Psoriatic Arthritis Recognition in Psoriasis Patients: GRAPPA Survey Findings

Trial

Review study, GRAPPA

20 October 2023 12:15

Bimekizumab: high rates of sustained response in PsA

Trial

Phase 3, BE OPTIMAL

Conference

EULAR 2023

Type

Peer-reviewed article

31 July 2023 06:46

Vascular inflammation may be characteristic of PsA

Presented By

Dr Nienke Kleinrensink, UMC Utrecht, the Netherlands

Conference

EULAR 2023

Type

Peer-reviewed article

31 July 2023 06:18

Obesity in PsA is increasingly affecting male patients

Presented By

Dr Marlene Stirnimann-Agustoni, University Hospital of Zürich, Switzerland

Conference

EULAR 2023

Type

Peer-reviewed article

31 July 2023 06:13

PsA patients: highest risk of developing NAFLD

Presented By

Mr Anthony Harrison, Leeds Teaching Hospitals NHS Trust, UK

Conference

EULAR 2023

Type

Peer-reviewed article

31 July 2023 06:09

Biologics in psoriasis: can they prevent joint involvement?

Presented By

Ms Kathleen Miao, Keck School of Medicine of USC, CA, USA

Conference

AAD 2023

Type

Peer-reviewed article

15 May 2023 12:46

Bimekizumab: Robust 1-year results in treating psoriatic arthritis

Presented By

Prof. Christopher Ritchlin, University of Rochester Medical Center, USA

Trial

Phase 3

Conference

ACR 2022

Type

News article

1 December 2022 14:33

Selective IL-23 inhibitor achieves long-term disease control in many patients with active PsA

Presented By

Dr Kim Papp, Probity Medical Research, Canada

Trial

KEEPsAKE 1; KEEPsAKE 2

Conference

EADV 2022

Type

Peer-reviewed article

5 November 2022 10:28

AI machine learning algorithm useful in early detection of PsA

Presented By

Dr Jonathan Shapiro, Maccabi Healthcare Services, Israel

Conference

EADV 2022

Type

Peer-reviewed article

5 November 2022 10:24

Alarmingly low activity in patients with non-inflammatory and inflammatory rheumatic disease

Presented By

Prof. Luca Quartuccio, University of Udine, Italy

Conference

EULAR 2022

Type

Peer-reviewed article

21 July 2022 19:31

How to treat enthesitis in 2022

Presented By

Prof. Dennis McGonagle, University of Leeds, United Kingdom

Trial

Phase 3, SEAM-PsA, EXCEED, SPIRIT-H2H

Conference

EULAR 2022

Type

Peer-reviewed article

21 July 2022 17:42

Baseline cardiovascular risk linked to higher rates of MACE in PsA and PsO patients receiving tofacitinib

Presented By

Prof. Lars Erik Kristensen , Copenhagen University Hospital, Denmark

Conference

EULAR 2022

Type

Peer-reviewed article

21 July 2022 17:30

Treat-to-target dose reduction effective in spondyloarthritis

Presented By

Dr Celia Michielsens , Sint Maartenskliniek, the Netherlands

Conference

EULAR 2022

Type

Peer-reviewed article

21 July 2022 17:21

Many RA and PsA patients have problems with their sex life

Presented By

Dr Carlos Valera-Ribera , Doctor Peset University Hospital, Spain

Conference

EULAR 2022

Type

Peer-reviewed article

21 July 2022 17:12

Psoriatic arthritis: significant improvement with bimekizumab

Presented By

Prof. Iain McInnes , Glasgow University, United Kingdom

Trial

Phase 3, BE OPTIMAL

Conference

EULAR 2022

Type

Peer-reviewed article

21 July 2022 14:36

EULAR 2022 Highlights Podcast

Presented By

Dr Rachel Giles, Medicom

Conference

EULAR 2022

22 June 2022 23:51

New insights into psoriasis comorbidity

Presented By

Prof. Joel Gelfand, University of Pennsylvania, USA

Conference

AAD 2022

Type

Peer-reviewed article

17 May 2022 12:12

Explaining arthropathy development through IL-4 and IL-13 blockade

Presented By

Dr Charlie Bridgewood, University of Leeds, UK

Conference

PFGC 2021

Type

Peer-reviewed article

3 February 2022 10:51

Patients on immunomodulators need 2 COVID-19 vaccinations before seroconversion

Presented By

Dr Ali Al-Janabi, University of Manchester, UK

Conference

PFGC 2021

Type

Peer-reviewed article

2 February 2022 15:22

Selective IL-23 inhibition normalises gene expression in active PsA

Presented By

Ms Michelle Miron

Trial

Phase 3, DISCOVER-1&-2

Conference

PFGC 2021

Type

Peer-reviewed article

2 February 2022 13:48

Selective IL-23 inhibition: a new option in active PsA

Presented By

Prof. Andrew Östör, Monash University, Australia

Trial

Phase 3, KEEPsAKE 1, KEEPsAKE 2

Conference

ACR 2021

Type

Peer-reviewed article

14 January 2022 10:52

Ustekinumab: highly efficacious in PSA independent of methotrexate

Presented By

Dr Michaela Köhm, Goethe-University Frankfurt, Germany

Conference

ACR 2021

Type

Peer-reviewed article

14 January 2022 10:48

B-cell depleting medication increases COVID-19 breakthrough infection outcome risk

Presented By

Prof. Jean Liew, Boston University, MA, USA

Conference

ACR 2021

Type

Peer-reviewed article

14 January 2022 10:45

PFGC 2021 Highlights Podcast

Presented By

Dr Rachel Giles, Medicom

Conference

PFGC 2021

22 December 2021 08:12

ACR 2021 Highlights Podcast

Presented By

Dr Rachel Giles, Medicom

Conference

ACR 2021

22 November 2021 16:18

Existing and upcoming small molecules in psoriasis

Presented By

Dr Enikö Sonkoly , Karolinska University Hospital, Sweden

Trial

POETYK PSO; PSOARING

Conference

EADV 2021

Type

Peer-reviewed article

18 November 2021 13:19

Faecal microbiota transplantation not effective in active peripheral PsA

Presented By

Dr Maja Skov Kragsnaes , University of Southern Denmark, Denmark

Trial

FLORA

Conference

EULAR 2021

Type

Peer-reviewed article

2 August 2021 21:08

IL-17 inhibitor effective in axial manifestations of psoriatic arthritis

Trial

Phase 3, MAXIMISE

Conference

AAD VMX 2021

Type

Peer-reviewed article

7 June 2021 13:00

Resolution of dactylitis or enthesitis is associated with improvements in joint and skin symptoms

Presented By

Prof. Dennis McGonagle, University of Leeds, UK

Trial

Phase 3, DISCOVER-1 & -2

Conference

ACR 2020

18 January 2021 10:51

Promising novel treatment option for psoriatic arthritis

Presented By

Prof. Philip J. Mease, University of Washington, USA

Conference

ACR 2020

Type

Peer-reviewed article

18 January 2021 10:51

Inflammatory disease as a risk factor for fractures

Presented By

Dr Giovanni Adami, University of Verona, Italy

Conference

ACR 2020

Type

Peer-reviewed article

18 January 2021 10:45

Ixekizumab shows sustained improvements in pain and fatigue at 3 years

Presented By

Prof. Ana-Maria Orbai, Johns Hopkins University School of Medicine, USA

Trial

SPIRIT-P2

Conference

EULAR 2020

Type

Peer-reviewed article

14 August 2020 14:15

Adalimumab added to methotrexate yields better results in PsA than methotrexate escalatio

Presented By

Dr Laura Coates, Oxford University, United Kingdom

Trial

Phase 4, CONTROL

Conference

EULAR 2020

Type

Peer-reviewed article

14 August 2020 14:09

Upadacitinib provides fast onset of improvement in psoriatic arthritis

Presented By

Prof. Iain McInnes, University of Glasgow, Scotland

Trial

SELECT-PsA-1

Conference

EULAR 2020

Type

Peer-reviewed article

14 August 2020 14:02

Secukinumab monotherapy as efficient as adalimumab

Presented By

Prof. Iain McInnes, University of Glasgow, United Kingdom

Trial

Phase 3, EXCEED

Conference

EULAR 2020

Type

Peer-reviewed article

14 August 2020 13:11

ECLIPSE trial: skin clearance independent of PsA status at baseline

Presented By

Prof. Kristian Reich

Trial

Phase 3, ECLIPSE

Conference

AAD 2020

Type

Peer-reviewed article

7 August 2020 13:12

Lowest risk of infection after therapy with an IL-12/IL-23 blocker

Presented By

Dr Yinzhu Jin, Brigham and Women´s Hospital and Harvard Medical School, Boston, USA

Trial

Cohort study

Conference

ACR 2019

Type

Peer-reviewed article

4 February 2020 23:42

Few serious infections in offspring with exposure to non-TNFi biologics or tofacitinib

Presented By

Dr Evelyne Vinet, McGill University, Montreal, Canada

Conference

ACR 2019

Type

Peer-reviewed article

4 February 2020 23:12

Psoriasis onset determines sequence of symptoms

Presented By

Prof. Umut Kalyoncu, Hacettepe University, Turkey

Conference

ACR 2019

Type

Peer-reviewed article

4 February 2020 23:07

Higher psychiatric comorbidity in women with PsA

Presented By

Prof. Mehmet Duruöz, Marmara University Hospital, Turkey

Conference

ACR 2019

Type

Peer-reviewed article

4 February 2020 22:50

Selective IL-23 blocker shows remarkable efficacy in patients with psoriatic arthritis

Presented By

Prof. Atul Deodhar, Oregon Health & Science University, USA

Trial

Phase 3, DISCOVER

Conference

ACR 2019

Type

Peer-reviewed article

4 February 2020 19:53

CARDAS study shows increased prevalence of cardiac valvular disorders in AS patients

Presented By

Mr Milad Baniaamam, Amsterdam University Medical Center, the Netherlands

Trial

CARDAS

Conference

ACR 2019

Type

Peer-reviewed article

4 February 2020 10:04

Efficacy and safety of ixekizumab versus adalimumab in patients with PsA

Presented By

Dr Roy Fleischmann, University of Texas Southwestern Medical Center, Dallas, USA

Conference

EULAR 2019

Type

Peer-reviewed article

4 September 2019 11:20

Efficacy and safety of bimekizumab in patients with active PsA

Presented By

Dr Christopher Ritchlin, University of Rochester Medical Centre, USA

Trial

Phase 2, BE ACTIVE

Conference

EULAR 2019

Type

Peer-reviewed article

4 September 2019 11:10

Filgotinib is efficacious and safe in PsA

Presented By

Prof. Philip Mease, Swedish Medical Center and University of Washington, Seattle, USA

Trial

Phase 2, EQUATOR

Conference

EULAR 2019

Type

Peer-reviewed article

4 September 2019 11:00

Ixekizumab improves signs and symptoms in TNFi-naïve PsA patients

Presented By

Dr Amanda Gellett, Eli Lilly, USA

Trial

Phase 3, SPIRIT-P2

Conference

EULAR 2019

Type

Peer-reviewed article

4 September 2019 10:50

Etanercept and methotrexate as first-line treatment in PsA

Presented By

Prof. Philip Mease, University of Washington, USA

Trial

Phase 3, SEAM-PsA

Conference

EULAR 2019

Type

Peer-reviewed article

4 September 2019 10:40

Unacceptable pain is common in patients with psoriatic arthritis

Presented By

Dr Tor Olofsson, Lund University, Sweden

Conference

EULAR 2019

Type

Peer-reviewed article

4 September 2019 10:33

NSAIDs consumption is linked to patient-assessed disease activity and decreases with use of TNF inhibitors

Presented By

Dr Olafur Palsson, University Hospital Reykjavik, Iceland

Trial

ICEBIO database

Conference

EULAR 2019

Type

Peer-reviewed article

4 September 2019 10:11

Advances in target-oriented therapy: psoriatic arthritis

Presented By

Prof. Wolf-Henning Boehncke, University of Geneva, Switzerland

Trial

ECLIPSA, TICOPA

Conference

SPIN 2019

Type

Peer-reviewed article

21 June 2019 23:48

Small molecules, apremilast, and TYK2

Presented By

Prof. Richard Langley, Dalhousie University, Canada

Trial

ESTEEM, PALACE, LIBERATE

Conference

SPIN 2019

Type

Peer-reviewed article

21 June 2019 09:45

IBD risk of treatment with IL-17 antagonists

Presented By

Dr Wolfgang Eigner, Medical University of Vienna, Austria

Conference

ECCO 2019

Type

Peer-reviewed article

9 May 2019 14:37

Plaque psoriasis – Efficacy of guselkumab

Trial

Phase 3, VOYAGE 1, VOYAGE 2

Conference

AAD 2019

Type

Peer-reviewed article

19 April 2019 20:06

Psoriasis and Biologics: The Beat Goes On

Presented By

Prof. Mark Lebwohl, Mount Sinai School of Medicine, USA

Conference

AAD 2019

Type

Peer-reviewed article

19 April 2019 14:06

Switching to biosimilar bDMARDs is safe and efficacious

Presented By

Prof. Kvien, University of Oslo and Diakonhjemmet Hospital, Norway

Trial

Phase 4, NOR-SWITCH

Conference

EULAR 2018

Type

Peer-reviewed article

24 August 2018 22:46